Shares in Amplitude Energy Ltd (ASX: AEL) have been a bit unloved over the past year, falling more than 40% over the period.

That has prompted the analysts at Morgans to have a look at the energy company, and they believe there is significant upside to be had by investing in this offshore gas producer.

What has been driving the Amplitude share price lower?

In a note to clients recently, Morgans said there had been some sizeable, albeit short-term catalysts recently which had pushed the share price lower, but added that the shares had de-rated, "to a level we view as unsustainable given the company's forward earnings profile".

Morgans' assessment of the value of the company had dropped 17% due to poor exploration results and weaker spot gas prices, but the shares had fallen 57% since a high in February.

In May, Amplitude bought half of the Artisan gas field in the offshore Otway Basin from Beach Energy Ltd (ASX: BPT) for $58.3 million, which Morgans said was a deal that made sense for the company.

Amplitude Managing Director Jane Norman said regarding the deal:

Producing Artisan through Amplitude Energy's existing infrastructure allows faster and lower-cost development of this gas for the east coast domestic market. Artisan development costs will significantly benefit from leveraging the existing East Coast Supply Project (ECSP) program and our readily-available infrastructure. This is a win-win for Amplitude, O.G. Energy and Beach with respect to optimising our respective Otway Basin positions. We expect to rapidly move to FID on the development phase of the ECSP over the next few months while the drilling of the Juliet and Annie wells is conducted, with Juliet now brought forward and drilling expected to commence by late July or early August.

Morgans said the deal de-risked the ECSP for Amplitude.

Amplitude shares looking cheap

Morgans added:

While the year-to-date share price performance has been disappointing, driven by gas reservation policy uncertainty and the ECSP drilling results, but in our view the share price pressure has outpaced the change in value and has increased the size of the long-term value upside on offer. While there remains great uncertainty around Australia's gas reservation policy, which could bring some downside to long-term domestic gas prices (potentially), it is hard not to believe we are near peak negativity on the topic sentiment wise (an appealing marker for value investors).

Morgans has a buy rating on Amplitude shares with a price target of $3, compared to $1.27 currently.

Amplitude is valued at $385.35 million.

The post This ASX gas company could more than double in value: Broker appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Tuesday
• Oil price crash sparks broker upgrades for ASX energy shares
• Why ASX 200 energy stocks like Woodside and Santos shares got smashed in June
• 5 things to watch on the ASX 200 on Wednesday
• 5 things to watch on the ASX 200 on Tuesday

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

When it comes to picking stocks that might have some serious upside, it pays to ask the professionals.

I've had a look through the broker reports that came out this week and have selected three ASX 200 companies that the analyst team at Macquarie thinks will do well going forward. 

Let's see what they're saying.

Santos Ltd (ASX: STO)

This oil and gas major recently announced it had hit continuous production at its Pikka oil project in Alaska, which was a major milestone for the company. 

The project is now producing about 20,000 barrels of oil per day, which will ramp up to 80,000 during the third quarter of 2026.

Santos Managing Director Kevin Gallagher said regarding the project:

Pikka is a high-quality, low-cost oil development with strong economics and long reserves life benefiting not only Santos and its joint venture partner Repsol, but also key stakeholders, including the State of Alaska and Alaska Native Corporations. The project is set to generate robust cash flows and support strong shareholder returns over the coming years.

Macquarie said in this week's note to clients that Santos had "solid sequential growth" in its second-quarter production. 

They added:

Currently, we view STO as tracking to the lower end of its CY26 guidance range, due to the longer asset commissioning/ramp times than expected when the guide was set.

They also added that due to relative share price weakness, Santos may yet again be in the sights of acquirers.

Macquarie has a price target of $9 on Santos shares compared to $7.07 at the time of writing.  

Pexa Ltd (ASX: PXA)

Shares in this property settlements technology company are down about 16% over a 12-month period, but the Macquarie team believes there is significant upside.

Macquarie said property settlements in New South Wales improved by 3.1% in June compared with the previous corresponding period, after a weak May.

Macquarie boosted its price target on the company to $19.30 from $19.05, compared with $10.87 at the time of writing.

The broker added, "formal commitment from additional Tier-1 lenders is likely to incentivise the other Tier-1 lenders to onboard with PXA quickly, driving rapid market share gains''.  

Aristocrat Leisure Ltd (ASX: ALL)

A recent investor day from this company "illustrated Aristocrat's dominant cross-channel position, and enterprise-wide approach to game development, which improves commercialisation of its market leading content''.

Macquarie said it saw market-share opportunities for Aristocrat in land-based gaming, but was more wary of the company's Product Madness mobile gaming division. 

The broker said Aristocrat was well-placed to deliver 10% to 15% earnings per share growth.

They also said the company would benefit from AI, with the benefits including "creativity enhancements, improved velocity to market, and advancing data analytics''.

Macquarie has a price target of $65 on Aristocrat shares compared to $61.38 at the time of writing.  

The post Three ASX 200 companies Macquarie says are a buy right now appeared first on The Motley Fool Australia.

More reading

• 2 ASX 200 stocks that could rise 31% and 121%
• 5 things to watch on the ASX 200 on Tuesday
• Here are the top 10 ASX 200 shares today
• Oil price crash sparks broker upgrades for ASX energy shares
• 5 things to watch on the ASX 200 on Monday

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group and PEXA Group. The Motley Fool Australia has positions in and has recommended PEXA Group. The Motley Fool Australia has recommended Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Shares in Echo IQ Ltd (ASX: EIQ) are more than 6% higher after the company said it had gained exclusive access to a large dataset that would materially enhance its cardiovascular product development.

Why are Echo IQ shares doing so well?

The company's shares have been performing strongly recently, shooting up by more than 50% when they announced a deal with fellow Australian imaging company Pro Medicus Ltd (ASX: PME).

The shares were trading at levels around $1.12 in mid-June but are now changing hands for $1.72, up 6.5% on Thursday.

Echo IQ said the new agreement with Advara Heartcare, "provides Echo IQ access to between 500,000 and 1,000,000 de-identified echocardiography studies and associated relevant clinical datasets''.

The company added:

The proposed dataset includes echocardiographic images together with associated clinical information, including de-identified patient demographics where applicable and appropriate, referral pathways, diagnostic findings and relevant clinical outcomes. Access to both large-scale imaging data and linked clinical datasets is expected to significantly enhance Echo IQ's ability to develop, train and validate future AI models across a broad range of cardiovascular conditions. The Company believes access to large, high-quality imaging datasets will become increasingly important as cardiovascular AI evolves from single-disease applications towards broader multi-condition diagnostic and predictive platforms. The Advara dataset is expected to materially strengthen the Company's future product development capabilities by providing a substantial imaging resources capable of further supporting algorithm development, model refinement and validation activities across multiple cardiovascular indications.

Strong deal flow good news for Echo IQ

The new agreement follows the Pro Medicus deal, under which the larger company agreed to invest an initial $10 million in Echo IQ through a subscription for secured convertible notes, with the right to subscribe for a further $10 million once Echo IQ had its EchoSolv HF product cleared by the US Food and Drug Administration.

EchoSolv HF is an AI-powered heart failure detection software.

Pro Medicus has also agreed to become a reseller for EchoSolv, "providing potential access to an extensive network of leading US health systems, academic medical centres and enterprise healthcare customers".

Echo IQ Chief Executive Officer Dustin Haines added at the time:

The execution of this binding Heads of Agreement with Pro Medicus represents a transformational milestone for Echo IQ and a significant validation of both our technology and long-term commercial strategy, while also providing exceptional financial flexibility to accelerate our commercialisation activities in the US.

Echo IQ also raised $110 million in new capital off the back of the Pro Medicus deal at $1.45 per share.

The post Up more than 550% in a year, why is this ASX biotech charging even higher? appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: Pro Medicus, BHP, Woolworths shares
• What are experts saying about these red hot ASX shares?
• Healthcare shares lead the ASX 200 again as sector rotation gathers pace
• 10 of the best ASX shares to buy in FY 2027
• Buy, hold, sell: Collins Foods, Karoon Energy, and Pro Medicus shares

Motley Fool contributor Cameron England has positions in Pro Medicus. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Northern Star Resources Ltd (ASX: NST) shares are trading higher after the company announced it would meet production guidance and had also appointed a new Chief Executive Officer and Chair. 

Activist investor has been applying pressure to Northern Star

Northern Star has been under pressure in recent months after activist investor Elliott Investment Management bought up a stake in the business and began agitating for a potential break-up of the business, as well as pushing for board renewal.  

Elliott also criticised Northern Star's production record after the company in January reduced FY26 gold production guidance from 1,700,000 to 1,850,000 ounces, down to 1,600,000 to 1,700,000 ounces. 

Northern Star then updated the market in March, saying that even hitting the lower end of that guidance, "will be challenging given weaker performance in the last two months''.   

The company added, "It remains the case that the company faces significant ongoing operational challenges particularly given the difficulty of maintaining throughput at required levels through the existing mill at KCGM''.

But on Thursday morning, the company released some good news on the production front, saying a strong June quarter meant it would meet guidance. 

The company said total gold sold for the June quarter was 433,000 ounces, bringing FY26 gold sold to 1,543,000 ounces. 

Northern Star also said it had $1.25 billion in cash and gold on hand at the end of the June quarter, and had repurchased $129 million worth of its shares during the quarter under its $500 million share buyback program.

It added that following a three-year construction period, the KCGM mill expansion project was tracking to schedule, with an increase in throughput from 13 million tonnes per annum to 27 million tonnes on track for commissioning in early FY27. 

Northern Star announces new leader

On the leadership front, the company said it had appointed Suresh Vadnagra to succeed Stuart Tonkin as Managing Director, effective 5 October, 2026.

The company said re the appointment:

Mr Vadnagra is a highly accomplished global mining executive with more than 25 years of experience spanning strategy, operations, major projects, transactions, business transformation and enterprise leadership across large, complex, multi commodity portfolios. He is currently Head of Glencore Nickel and Zinc Industrial Assets based in Switzerland, with responsibility for a diverse global portfolio of more than 25 operations spanning open pit and underground mines, smelters and refineries. Prior to his role at Glencore, Mr Vadnagra was the Chief Technical and Projects Officer at Newcrest, where he was accountable for Newcrest's major projects, technical teams and technology.

Northern Star also announced that Michael Ashforth would succeed Michael Chaney as Chair, with effect from the conclusion of this year's Annual General Meeting in November. 

Broker Morgans has a $26 per share price target on Northern Star shares, saying the company has a compelling medium to long-term growth story. 

Northern Star Resources shares were 2.5% higher at $19.28 in early trade.

The post Why are Northern Star Resources shares higher today? appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Tuesday
• 5 things to watch on the ASX 200 on Monday
• Top brokers name 3 ASX shares to buy next week
• 9 ASX 200 shares with renewed buy ratings for FY27
• Here are the top 10 ASX 200 shares today

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Building a share portfolio that can complement a salary, or even, hopefully, replace it, is a common goal for many share market investors.

For investors who are looking for an income stream rather than capital gains, it pays to go with Australian-based companies that have committed to paying dividends over the medium to long term, and exchange-traded funds specifically set up to pay high dividends.

How much do you need to generate $500 per week?

So, let's look at the yields you'll need for a $500 per week return. This, of course, translates to $26,000 a year.

So, what dividend yields do stocks normally pay?

According to S&P Dow Jones, the S&P/ASX 200 Index (ASX: XJO) delivered an average trailing dividend yield of 4.15% from July 2011 to December 2024.

But this includes plenty of companies that pay low or no dividends.

I'd argue it's quite possible to aim for a portfolio that delivers a dividend yield of around 5%, while also including some companies that pay a lot more.

At a 5% yield, you'd need a portfolio worth $520,000 to deliver $500 a week.

At a 7.5% yield you'd need just $346,666.

At a 10% yield you'd need just $260,000.

While there are stocks which pay more than a 10% yield, these are few and far between, and I'd argue that those sorts of yields are likely to be unsustainable.

What ASX shares can I invest in to achieve $500 in income?

On the ETF front, the Australian Dividend Harvester Active ETF (ASX: HVST) is currently paying a yield of 5.8%, which sits firmly in the ballpark of returns targeted.

There is also the Vanguard Australian Shares High Yield ETF (ASX: VHY) which has major holdings in BHP Group Ltd (ASX: BHP), Commonwealth Bank of Australia (ASX: CBA) and Rio Tinto Ltd (ASX: RIO).

This ETF currently pays a dividend yield of 5.47%.

Another income-focused security is WAM Capital Ltd (ASX: WAM), which is currently paying a trailing dividend of 10.4%, 60% franked.

Among the miners Fortescue Ltd (ASX: FMG) pays a healthy trailing dividend of 6.37% currently, while toll roads operator Atlas Arteria Ltd (ASX: ALX) – should it survive a current takeover approach – has committed to paying a dividend of 60 cents per share, or well over 10%.

Three other companies which are currently paying out better than 5% dividends are AGL Energy Ltd (ASX: AGL), APA Group (ASX: APA), and Stockland Corporation Ltd (ASX: SGP).

Other solid companies which pay a bit less than we're after are Telstra Ltd (ASX: TLS) with a yield of 3.93% and Westpac Banking Corporation (ASX: WBC) which pays a trailing yield of 4.37%.

So as you can see, with some diversification across stocks such as these, a 5% dividend yield appears to be within reach.

The post How to get started with a portfolio delivering $500 a week in passive income appeared first on The Motley Fool Australia.

More reading

• Property or ASX shares? Here's why I'd choose the share market
• How should I invest my money in FY27?
• How much is needed in superannuation to target a $70,000 annual passive income?
• ASX financials went from the best sector in FY25 to negative growth in FY26. Here's what changed
• 5 of the best investments on the ASX right now to complement your superannuation

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended Apa Group and Telstra Group. The Motley Fool Australia has recommended BHP Group and Vanguard Australian Shares High Yield ETF. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Telix Pharmaceuticals Ltd (ASX: TLX) recently hosted a webinar for investors, highlighting recent developments in the use of two of its compounds for the treatment of aggressive brain cancers.   

New brain cancer therapy in development

Interestingly, the biotech company did not release anything specific to the ASX for those who didn't catch the webinar, but for the brokers that did, they came away with a positive impression. 

UBS followed up the webinar with a note to its clients on Telix, pointing out that glioblastoma – the cancer in question – affected about 12,000 people per year. 

They also noted that the current standards of care "do not provide meaningful long-term survival benefit''.

UBS added: 

The event highlighted 2 clinical assets with potential to transform the field – TLX-Tx and Pixclara (TLX101-Px). We believe the Street has not assigned much credit to both programs, and we expect Pixclara approval on Sept 11th to drive some upside while clinical data from TLX101-Tx could drive long-term upside. TLX101-Tx was a key highlight of the presentation, including the ongoing Phase 3 IPAX BrIGHT trial, evaluating combo with lomustine in difficult-to-treat, recurrent glioblastoma.

UBS said Telix management stressed the significant unmet need in the treatment of such cancers.

They also added:

Notably, management noted that the trials' design got FDA buy-in following discussions, where dose optimization was recommended as a first step.

Second broker also impressed

RBC Capital Markets also sat in on the webinar and came out with a positive note to its clients.

They said:

MRI is the gold standard for imaging of glioblastomas, however there are some limitations with MRI. In Europe, MRI is also supplemented with use of molecular imaging which is very valuable and can help distinguish disease progression from treatment related changes. Use of molecular imaging also helps the patient to visualise where the treatment can go and makes a big difference in the doctor's opinion. In our view, this feedback supports the use of TLX101-Px if it is approved in the US.

They also noted there hadn't been a significant step forward in glioblastoma treatment since 2008.

They added:

The last treatment advancement was in 2005 with temozolomide being added to chemotherapy which added 2.5 months to median survival. Therefore TLX's potential glioblastoma therapeutic treatments are welcome advances. A case study was shown with one IPAX-Bright patient showing a near complete response and is alive 23 months since starting treatment with TLX101-Tx. The trial design for IPAX-BRIGHT involved a high level of consultation with the FDA.

How much are Telix shares worth?

RBC has a $18 price target on Telix shares, while UBS is much more bullish at $31.

Telix shares were trading at $17.25 on Wednesday, up 44.4% since the start of January but down 28.3% over a year.

Telix is valued at $5.63 billion.

The post Up 44% year to date, how high could Telix shares go? appeared first on The Motley Fool Australia.

More reading

• These are the 10 most shorted ASX shares
• Here are the top 10 ASX 200 shares today
• Healthcare shares lead the ASX 200 again as sector rotation gathers pace
• Up 55% in 2026! Why this ASX healthcare stock is climbing again
• Forget CSL shares. These 2 ASX healthcare stocks could double your money

Motley Fool contributor Cameron England has positions in Telix Pharmaceuticals. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Shares in Paladin Energy Ltd (ASX: PDN) and Boss Energy Ltd (ASX: BOE) have made strong gains after both were upgraded by broking house RBC Capital Markets. 

And while the shares have already made substantial gains, RBC has bullish share price targets for each, which are well above current levels. We'll get to those shortly.

First, let's look at what RBC is saying. 

Uranium demand is growing on the back of new reactor projects

The broker said in its new research note to clients that momentum in the uranium sector is building, with "policy catalysts are stacking faster than supply can respond''.

For example, the US Department of Energy has made a US$17.5 billion commitment to fund 10 new AP1000 nuclear reactors, while Canada is also planning 10 new reactors by 2040.

RBC added:

Sovereign and hyperscaler demand are collectively adding demand that a structurally under-supplied market simply cannot absorb. Execution risk is pervasive, and new mines take decades to develop. The term market knows this: fixed-price deals are already transacting at $100/lb while the published $95/lb indicator lags reality. We raise our long-term price forecast to US$110/lb.

RBC said India had also made a commitment to grow its nuclear capacity 10-fold by 2047.

And in the technology market, uranium producer Cameco had "confirmed multiple term sheets with major tech companies, with the broader tech-nuclear partnership pipeline across Meta, Microsoft, Google, Amazon, and Switch spanning a combined framework of over 30 GW''. 

What does this mean for ASX uranium shares?

In light of its upgraded uranium price outlook, RBC has upgraded Paladin to an outperform rating.

RBC said the company's Atlas discovery gave greater confidence in its Patterson Lake South project, underpinning life of mine production materially higher than current estimates. 

RBC expects FY27 guidance to come in at 5.5 million pounds of uranium at a cost of US$45 per pound to produce.

RBC has a price target of $13.50 on Paladin compared to the current share price of $9.88, which is up 6.2% on the day.

With regard to Boss Energy, RBC said the company's fourth-quarter results should show some recovery from the weather-impacted third quarter.

RBC added: 

Sales volumes are forecast at about 422klb at a realised price of about US$75/lb, driving revenue up about 12% to about US$31.6m. We upgrade Boss to Sector Perform on an improved uranium price outlook, though near-term production remains constrained pending the revised feasibility study expected in 1Q FY27.

RBC has a price target of $1.30 on Boss shares compared to $1.10, up 8.9% on the day.

The post Why are these 2 ASX uranium stocks shooting higher today? appeared first on The Motley Fool Australia.

More reading

• These are the 10 most shorted ASX shares
• Boss Energy shares surging 12% today on big uranium news
• 6 ASX shares upgraded by experts this week
• Here are the top 10 ASX 200 shares today
• Here are the 10 most shorted ASX shares

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Amazon, Cameco, Meta Platforms, and Microsoft. The Motley Fool Australia has recommended Amazon, Meta Platforms, and Microsoft. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Gold has fallen in value by about 25% since its January highs, but that doesn't mean there aren't bargains to be had among the Australian gold producers. 

Here are the ones Morgans has a buy rating on. 

Newmont Mining Ltd (ASX: NEM)

Morgans said the world's largest gold producer offers "unmatched tier-1 asset diversification", free cash flow of about 15%, and an ongoing US$6 billion buyback.

They added: 

A defensive, high-quality gold exposure for investors in a volatile market.

They have a price target of $198 for Newmont shares compared to $134.18 currently.

Northern Star Resources Ltd (ASX: NST)

This company has a "compelling medium to long-term growth story" and trades at a material discount to net asset value, Morgans said. 

However, a push for a breakup of the company by activist investor Elliott and the ongoing search for a new managing director inject some uncertainty.

Morgans added:

A potential sale process represents the clearest catalyst for immediate upside.

They have a price target of $26 on the company compared to $18.86 currently. 

Evolution Mining Ltd (ASX: EVN)

This is Morgans' preferred large-cap pick, "combining low-cost operating base, consistent execution, net cash balance sheet and meaningful copper exposure''.

Morgans said recent sector weakness provides a compelling entry point.

They have a price target of $15 on the company compared to $11.62 currently.

Ramelius Resources Ltd (ASX: RMS)

Morgans rates Ramelius as a high-quality, low-cost producer, "with one of the strongest medium-term production growth profiles in the sector''.

They added:

The recent pullback provides an attractive entry point into a disciplined management team with a robust balance sheet.

They have a price target of $5.80 on the company compared to $2.92 currently.

Regis Resources Ltd (ASX: RRL)

Regis, Morgans said, provides direct, unhedged leverage to the gold price through a portfolio of strong, cash-generative assets.

Morgans has a price target of $9.39 on Regis compared to $5.93 currently.

Catalyst Metals Ltd (ASX: CYL)

Morgans said this company has a "compelling mid-cap growth story underpinned by production expansion at Plutonic and the high-grade Trident development''.

They added:

We see recent sector weakness as an attractive opportunity to accumulate in this value name.

Morgans has a price target of $13.58 on the company compared to $4.89 currently.

Where to from here for the gold price?

Morgans has reduced its forecast for the gold price for the remainder of the year, reducing it from US$4750 per ounce to US$4250 per ounce. 

The current spot price of gold is US$3994.53. 

The post 6 ASX gold stocks Morgans rates as a buy appeared first on The Motley Fool Australia.

More reading

• This ASX gold stock could soar 60% thanks to a big announcement
• 5 things to watch on the ASX 200 on Tuesday
• Gold, cash, and a takeover twist: Why this ASX 200 gold stock is climbing today
• Move over Regis Resources! Vault Minerals shares leaping 11% as Genesis Minerals' lobs $5.6 billion takeover bid
• Regis Resources hits top end of FY26 guidance

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Space Exploration Technologies Corp (NASDAQ: SPCX) shares had another strong session in trading overnight, and if market watchers are to be believed, there's likely to be ongoing support for the stock over the next week or so.

Why are traders providing support for SpaceX shares?

This is because the stock is scheduled to be included in the Nasdaq 100 Index from the beginning of trade on Tuesday 7 July, meaning funds which track the index will be compelled to buy the stock.

Such funds include the US$800 billion Invesco QQQ Trust, and JP Morgan has reportedly estimated there will be at least US$4.3 billion in stock purchases by index-tracking funds.

The US$4.3 billion figure may not seem large relative to SpaceX's US$2.25 trillion market capitalisation, but it is significant given that the company has only listed a fraction of its shares in the public float, with US$75 billion in shares offered to new investors.

SpaceX was fast-tracked into the Nasdaq 100, with a rule change adopted by the Nasdaq in May allowing for its rapid inclusion.

How have SpaceX shares fared so far?

SpaceX shares have performed well since they were listed on June 12, hitting a high of US$225.64 in the days immediately following their listing before settling back.

Overnight the shares were 6.2% higher at US$180.86, still well above the US$135 initial public offer price.

As well as the pressure from traders buying in ahead of the Nasdaq 100 inclusion, Bloomberg was also reporting overnight that SpaceX was in talks with Charter Communications to offer a satellite-connected mobile phone service.

The Charter deal, if it eventuates, would be with SpaceX's Starlink division, which is the only one of the company's three divisions which is currently profitable.

How are the company's financials?

SpaceX overall posted a US$2.59 billion loss on revenue of US$18.7 billion in 2025.

And the company's initial public offer prospectus shows that for the first three months of 2026, the Space division lost US$662 million, the AI division lost US$2.47 billion, and the connectivity division made a profit of US$1.19 billion.

The company believes its business opportunity is huge however, saying in the prospectus, "We believe that space represents the largest economic frontier in human history", and suggesting that they will be building AI infrastructure in space, powered by the "virtually limitless" power of the sun, for the benefit of mankind.

The company added:

Our mission is to build the systems and technologies necessary to make life multiplanetary, to understand the true nature of the universe, and to extend the light of consciousness to the stars. To do this, we have formed the most ambitious, vertically integrated innovation engine on (and off) Earth with unmatched capabilities to rapidly manufacture and launch space-based communications that connect the world, to harness the Sun to power a truth-seeking artificial intelligence that advances scientific discovery, and ultimately to build a base on the Moon and cities on other planets.

The post Why is the SpaceX stock price trading higher? appeared first on The Motley Fool Australia.

More reading

• SpaceX will be included in the Nasdaq index this week. Here's what that means for ASX investors
• SpaceX shares are rocketing – how can Aussie investors get exposure?
• 5 things to watch on the ASX 200 on Wednesday
• 5 things to watch on the ASX 200 on Monday

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Long-suffering CSL Ltd (ASX: CSL) shareholders received another blow this week when the company revealed its Tavneos product could be blocked from sale in the European Union. 

It's the latest in a string of bad news for the company over the past year or so, which has resulted in the share price dipping about 50%.  

The question is, are the shares good buys at their current depressed levels, or are they fully priced?

The analyst team at Macquarie has an opinion on that, which we'll get to shortly.

First, let's look at what was announced this week.

Another setback for the company

CSL said in a statement to the ASX:

On 26 June 2026, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued an opinion recommending the revocation of the EU marketing authorisation for Tavneos. This opinion follows CHMP's review under Article 20 of the handling of data in the pivotal Phase 3 Advocate clinical trial supporting the product's approval.  

CSL points out that the trial was done by a separate company, and it sells the product under licence.

It said the European Commission would review the CHMP opinion and issue a final decision "in due course".

CSL's Head of Research & Development, Dr Bill Mezzanotte, said: 

While we are disappointed in the outcome of the Article 20 procedure, we will respect the regulatory process and are committed to implementing it in full. We recognise this is a difficult moment for the community, as Tavneos has played an important role for patients living with ANCA-associated vasculitis, a life-threatening disease with limited treatment options. VFMCRP (Vifor) and CSL remain focused on bringing innovative treatment options to patients living with rare diseases. Patient care remains our highest priority, and we are working closely with regulatory authorities, healthcare professionals and patient organisations to ensure a compliant and appropriate treatment transition, along with ongoing support for patients.

The company said sales revenue for Tavneos for FY26 was expected to be about $145 million.

CSL added:

Further detail, including impairment of TAVNEOS intellectual property, will be provided as part of CSL's 2026 Full Year results in August 2026. This announcement does not change the estimated impairment provided to investors on 11 May 2026.

CSL shares look fully valued

The Macquarie team said in their note to clients that a ruling from the European Commission was likely within 60 days and a decision striking out the treatment was "highly probable". 

Macquarie has adjusted its FY27 forecasts for CSL to account for a 65% reduction in Tavneos revenue, "with no new patients treated in Europe effective immediately''. 

They said:

We reiterate our Neutral rating amid significant uncertainty in near term earnings across the core business segments (IG, albumin) and ongoing competitive risks in the medium term.

Macquarie has a price target of $114 on CSL shares compared with $115.39 on Tuesday morning.  

CSL is valued at $55.26 billion. 

The post Where does Macquarie think CSL shares will go from here? appeared first on The Motley Fool Australia.

More reading

• How to tell if an ASX share is cheap or a value trap
• 2 ASX healthcare shares crashing, now bouncing: buy, hold or sell?
• ASX healthcare shares have jumped 21% since June. Can the recovery continue?
• After losing half their value, can CSL shares reclaim $275?
• 3 ASX shares down at least 50% in FY26

Motley Fool contributor Cameron England has positions in CSL. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Macquarie Group. The Motley Fool Australia has recommended CSL and Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Shaw and Partners has released a research report on two Africa-focused uranium companies, with very bullish share price targets for each. 

And for one, as you'll soon see, that share price target could be just the beginning.

Let's have a look at what they're saying. 

Atomic Eagle Ltd (ASX: AEU)

This company's main focus at the moment is the Muntanga uranium project in Zambia.

Atomic Eagle released the results of a feasibility study into the project in March, which outlined a US$282 million, 2.2 million pound per year open-pit mining operation with a 12-year mine life.

Shaw and Partners said the company kicked off a 30,000m drilling program at Muntanga in April, which was "the most significant exploration campaign at Muntanga in nearly 20 years''.

They added:

The objective is to double the current 58.8Mlb resource to underpin a significantly larger 4–5Mlbpa development scenario that would materially improve project economics through economies of scale.

Shaw and Partners said further drilling results at the Chisebuka target showed that it could be as large as 15 million pounds, "which would make it a handy satellite deposit to the main Muntanga and Dibbwi East deposits''.

And while Muntanga is the main game at the moment, the company also owns the Madaouela deposit in Niger, which hosts about 120 million pounds of uranium at an average grade of 1,400ppm, "making it one of the highest-grade undeveloped uranium deposits globally". 

Shaw and Partners added:

We currently have zero value for Madaouela in our $1.40 Atomic Eagle valuation, but if Atomic Eagle successfully negotiates a return of the project, then it could result in a substantial uplift in our valuation.

Atomic Eagle shares are changing hands for 42.5 cents at the time of writing.

Bannerman Energy Ltd (ASX: BMN)

This uranium company recently released an update about construction works at its Etango uranium project in Namibia. 

Shaw and Partners said the early works were tracking to budget and on schedule.

They added: 

Etango is on-track to be in production in 2028, which looks like to be perfect timing for the coming uranium super cycle. The Etango Uranium Project is one of the few greenfield uranium projects that will be in production this decade. The project is fully funded and has one of the best offtake agreements ever negotiated in the sector with its JV partner CNNC.

Shaw and Partners said a final investment decision for the project was "now a formality with the last remaining conditions precedent for completion of the JV with CNNC to be completed''.

Shaw and Partners has a $6.50 price target on Bannerman shares compared to $3.15 at the time of writing.

The post These 2 ASX uranium companies could deliver 100% to 200% returns: broker appeared first on The Motley Fool Australia.

More reading

• 3 reasons to buy this beaten down ASX 300 uranium stock today
• Buy, hold, sell: Bannerman Energy, Saluda Medical, Bapcor shares
• Top brokers name 3 ASX shares to buy next week
• Leading brokers name 3 ASX shares to buy today
• How high does UBS think this ASX uranium share will go?

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Africa has turned out to be a happy hunting ground for ASX-listed gold producers in recent years, with some of the companies starting to build some real scale.  

The team at Macquarie has had a look at the sector and singled out four companies they believe could deliver outsized share price gains. 

They are also speculating that the conditions are right for elevated returns of capital and potentially M&A to extend the operating life of some of the assets. 

Let's see which companies they like. 

Perseus Mining Ltd (ASX: PRU)

The Macquarie team said they see earnings for Perseus "hockeysticking beyond FY27", while cash would build to about US$1 billion in FY26. 

They added, "Perseus may become more active in developing/ acquiring ounces to sustain Sissingué beyond 2030'', given its large cash haul.

Macquarie is expecting Perseus' production to grow a compound 5% per year over the next three years, "driven by Nyanzaga entering production in 1QCY27 offsetting declining production at existing operations''.

They said the company has brownfield and greenfield expansion options, "which would seek to extend the mine-lives of Yaouré, Sissingue and Edikan, adding upside risk to our longer-term outlook''. 

They added:

Additionally, given PRU's balance sheet strength, and recent appetite for M&A targeted growth, we would not rule out a hub-and-spoke style model within Cote d'Ivoire, which would aim to maintain throughput across its existing mill infrastructure.

Macquarie has a price target of $6 on Perseus shares compared to $4.90 currently.

Resolute Mining Ltd (ASX: RSG)

Macquarie said Resolute has some issues to contend with, including instability in Mali, which had already affected the delivery of equipment and consumables. 

While the company lowered its second-quarter production outlook, it reiterated CY26 guidance of 195,000 to 210,000 ounces of gold for the calendar year.

Macquarie added:

With the development of Doropo (first production 2HCY28), RSG's reliance on Syama from an earnings perspective decreases, which should help to provide stability to production and earnings going forward.

Macquarie has a price target of $1.55 on Resolute shares compared to 95 cents currently.

West African Resources Ltd (ASX: WAF)

Macquarie said West African Resources shares were trading "materially below its 5-year historical multiple of 3.9x" EBITDA.

The analyst team added:

Despite production and costs that beat consensus expectations in the 1QCY26 result, we believe the market is hesitant given the recent developments in Burkina Faso. We anticipate this to dominate sentiment in the near-term. In 1QCY26, WAF released a 10-year production outlook, which highlighted a +500kozpa from ~CY27 onwards.

Macquarie has a $4 price target on West African shares compared to $2.69 currently.

Turaco Gold Ltd (ASX: TCG)

Turaco recently released a prefeasibility study for its Afema project in southeast Côte d'Ivoire, setting out the case for a mine producing more than 200,000 ounces of gold per year. 

In terms of the mine's revenue generation, the company published figures for a range of gold prices, but at US$4,000 per ounce – close to the current spot price of US$3971.22 – the mine would generate gross revenue of US$8.095 billion over its life of 10.3 years. 

The project would also have a payback period of 10 months, or 17 months if the gold price were US$3,000 per ounce.

Macquarie said the study detailed a larger throughput than they had modelled.

They added:

We anticipate as the business progresses through definitive feasibility study and additional permitting, ramp-up and steady-state production, its valuation will expand in line with peers like Perseus, which trades on a current multiple of A$802/oz.

Macquarie has a price target on Turaco shares of $1 per share compared to 45 cents currently.

The post 4 Africa-focused ASX gold stocks Macquarie says could outperform appeared first on The Motley Fool Australia.

More reading

• West African Resources posts June 2026 quarter gold production update
• 9 ASX 200 shares with renewed buy ratings for FY27
• Here are the top 10 ASX 200 shares today
• Here are the top 10 ASX 200 shares today
• 7 ASX shares downgraded by brokers this week

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia has recommended Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Shares in Brazilian Critical Minerals Ltd (ASX: BCM) were charging higher on Tuesday morning after the company published a bankable feasibility study into its Ema project, which said it had "exceptional economics''. 

Long-life, low-cost project

The study indicated that the project would be developed in two stages, with the first stage costing just US$74 million to build and having a payback period of six months.  

The project would produce total rare earth oxides at a cost of US$8.84 per kilogram, which the company said was among the lowest costs globally. 

A second stage that would double production would cost just US$27 million.

The company said regarding the study:

The bankable feasibility study confirms Ema as a long-life, economically resilient rare earth project, advancing BCM's pathway toward development and strengthening its exposure to critical minerals underpinning global electrification trends. The BFS incorporates a comprehensive suite of technical, operational and engineering initiatives designed to optimise project economics, de-risk future development pathways and support progression toward a disciplined Final Investment Decision (FID). The study follows a pivotal year for the Ema development team, including the successful completion of an extensive three-month in-situ recovery field trial program.

The company said in a statement to the ASX that the study highlights the potential for Ema to "emerge as one of the Western world's lowest-cost rare earth projects supplying downstream-compatible mixed rare earth carbonate product''.

The mine was expected to operate for 20 years and to produce, on average, EBITDA of US$219 million per year.

Brazilian Critical Minerals Managing Director Andrew Reid said: 

The results of the Bankable Feasibility Study further reinforce our belief that Ema has the potential to emerge as one of the most compelling rare earth development projects globally. The study highlights a combination of low capital intensity, low operating costs, strong projected cashflow generation and robust financial returns, positioning Ema favourably amongst both existing producers and emerging rare earth projects worldwide. Importantly, these outcomes are underpinned by the successful application of in-situ recovery (ISR), a development approach that significantly reduces mining intensity, lowers infrastructure requirements and provides a scalable lower risk pathway to long-term production. Ema's financial performance is particularly significant given the conservative assumptions incorporated within the study and the substantial remaining upside associated with resource expansion, wellfield optimisation, reagent recycling initiatives and future production growth.

Important new source of minerals

Mr Reid added that the mine would be of strategic importance as a source of rare earths outside of China, which has been a key focus for Western governments.

Brazilian Critical Minerals shares traded as high as 5.9 cents, up 25.5%, before settling back to be 17% higher at 5.5 cents. The company is valued at $92 million.

The post Up more than 400% over a year, why is this ASX rare earths share surging almost 20% higher? appeared first on The Motley Fool Australia.

More reading

• Qube Holdings: Supreme Court approves takeover scheme
• Summerset Group delivers Q2 update
• West African Resources posts June 2026 quarter gold production update
• Lynas Rare Earths inks $50m deal for new Malaysian magnet factory
• Netwealth posts strong FUA growth and secures Morgan Stanley platform deal

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Shares in Judo Capital Holdings Ltd (ASX: JDO) copped an absolute shellacking last week when the company downgraded its profit expectations and upped its cost of risk substantially.

The shares fell more than 40% in the session last Thursday and have failed to recover substantially since then.

So are they now going for a bargain? The team at Morgans seems to think so. We'll get to their analysis and price target for the company shortly.

First, let's look at what the company announced.

Tough times for the challenger bank

Judo said in its statement to the ASX last week that its cost of risk would now be $116-$122 million, "reflecting an increase in specific provisions primarily driven by three exposures across different sectors that have recently emerged, as a result of customer specific developments''.

Judo said it now expected profit before tax to be $163-$169 million, or about 30% up on FY25. This is down from previous guidance of $180-$190 million.

The company also said profit in FY27 was expected to be $210-$220 million, up another 30%, "as the Bank continues to deliver strong growth and operating leverage during a period of economic uncertainty''.

Judo Chief Executive Officer Chris Bayliss said:

We continue to see strong underlying momentum in the business. Recent credit outcomes have been driven by a small number of customers, who we are actively working with. These exposures have deteriorated subsequent to the customer-by-customer review undertaken in the third quarter and reflect recent, borrower-specific developments. "While today's update is partly a result of the macro environment, it is nevertheless disappointing. Regardless, we remain confident in the strength of our underlying business and the quality of the portfolio. We have a proven customer value proposition, are profitable and well capitalised, and have a clear path to achieving a return on equity in the low-to-mid teens.

Shares looking cheap

Morgans has this week released a research note looking at Judo and said the share price decline after the announcement was "vicious" especially considering the weakness in the share price since February.

The analyst team said Judo's forecast for FY27 earnings was materially below consensus forecasts of $255 million, and said, "the miss is more stark when considering that two years ago consensus was expecting $291 million profit before tax for FY27''.

The analysts said they had cut their price target for Judo Capital shares by 32% to $1.47, which is still well above the current level of 91 cents.

They added:

Short-term target price $1.47/share, but we think by the end of this decade JDO could be worth over $2/share. JDO is higher risk and more cyclically exposed than the major banks but investors are compensated by higher potential returns at current prices.

The post Is it time to buy the dip on Judo Capital shares? appeared first on The Motley Fool Australia.

More reading

• Judo Bank shares rise despite Morgan Stanley price target cut
• 7 ASX shares downgraded by brokers this week
• 2 ASX shares highly recommended to buy: Experts
• What happened with ASX 200 bank stocks CBA and Westpac shares in June?
• Top brokers name 3 ASX shares to buy next week

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Accessing superannuation can seem like a long way off for many people, but the beauty of that is you've got plenty of time to prepare.

Starting early and reaping the benefits of compound interest are key to ending up with a superannuation nest egg that will furnish you with a comfortable retirement, but it's good to know what that actually means.

The Association of Superannuation Funds of Australia (ASFA) regularly publishes its retirement standard, which currently estimates that homeowners aged 65 and over now need $77,375 annually for a comfortable retirement as a couple, and $54,840 for a single.

Using our yardstick of $1500 per week, this would put a single person firmly in comfortable territory, which is measured by assessing the affordability of things like top-level private health insurance, a reasonable car, and the ability to travel occasionally.

By the numbers

But how much in investments do you need to earn $1500 a week, or $78,000 a year?

Using a dividend yield of 5% per year, you'd need $1.56 million in your super to reap $78,000 a year, assuming there was no drawdown of capital.

So is 5% achievable? According to S&P Dow Jones, the S&P/ASX 200 Index (ASX: XJO) delivered an average trailing dividend yield of 4.15% from July 2011 to December 2024.

But this includes plenty of companies that pay low or no dividends. I'd argue it's quite possible to aim for a portfolio that delivers a dividend yield of around 5%, while also including some companies that pay a lot more.

You also have to take into account that for some retirees, superannuation earnings and distributions are tax-free.

Let's see how this affects the dividend payment of a company like Westpac Banking Corp (ASX: WBC).

Westpac pays a trailing dividend yield of 4.38%, according to the ASX website.

But Westpac has already paid 30% company tax on that dividend, which gets refunded to the retiree, boosting the dividend yield to 6.26%.

Aiming for income

There are also securities that aim specifically for a high dividend yield. One of these is the Australian Dividend Harvester Active ETF (ASX: HVST).

HVST aims "to exceed the net income yield of the broad Australian share market on an annual basis, paid monthly''.

Currently, its gross annual yield is running at 7.4%.

Another income-focused security is WAM Capital Ltd (ASX: WAM), which is currently paying a trailing dividend of 10.3%, 60% franked.

When it comes to companies, I've also recently written about three that are paying out better than 5%. These were AGL Energy Ltd (ASX: AGL), APA Group (ASX: APA), and Stockland Corporation Ltd (ASX: SGP).

At a 5% fully franked yield, the grossed-up yield increases to 7.1%, which would reduce the lump sum needed to generate a $78,000 yearly income to $1.09 million.

The post How much do I need in my superannuation to get $1500 per week in passive income? appeared first on The Motley Fool Australia.

More reading

• Property or ASX shares? Here's why I'd choose the share market
• How much is needed in superannuation to target a $70,000 annual passive income?
• ASX financials went from the best sector in FY25 to negative growth in FY26. Here's what changed
• Better buy? NAB vs Westpac shares
• Property prices are falling. Here are the ASX shares most affected

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended Apa Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Good drilling results at Polymetals Resources Ltd's (ASX: POL) flagship Endeavour Mine in New South Wales have impressed the analysts at Shaw and Partners, who believe the company's shares are undervalued.

New mining zone being defined

Polymetals last week issued a statement to the ASX saying that the first 12 holes drilled from underground at the mine had confirmed broad zones of high-grade silver-lead-zinc mineralisation.

The mineralisation is in the upper main lode, adjacent to the existing mine development, the company said.

Some of the best assay results include 45.2m at 436 grams per tonne of silver equivalent, and 33m at 439 grams per tonne.

The company said regarding the work program:

The drilling program is testing an area that has historically been considered largely sterilised following ground collapse during previous mining operations in 1996. Recent reinterpretation of historic mine data suggested the extent of the collapse may have been significantly smaller than previously assumed. This has created the opportunity to define substantial volumes of in-situ mineralisation which remain intact. Results from the first 12 holes  completed in the current 34-hole campaign have returned major silver-lead-zinc intersections. These results indicate high-grade mineralisation persists adjacent to the interpreted collapse boundaries and remain accessible from existing underground development, enhancing the potential to convert this area into mining inventory.

Polymetals Executive Director Jess Oram said all drill holes bar one had returned significant mineralisation.

She added:

What makes these results particularly important is their location. The mineralisation occurs within an established mining environment, close to existing infrastructure and immediately adjacent to the high-grade Upper North Lode. The ongoing 34-hole drilling program is designed to define the scale and continuity of this mineralisation. Continued success has the potential to support a meaningful addition to Endeavor's future mining inventory.

Shaw and Partners said the location of the recent drilling, next to the existing mine operations, meant the capital expenditure to mine the area should be low and would accelerate the development timeline.

They added:

Moving forward, Polymetals plans to finalise the remaining 22 drill holes to map out the exact scale and continuity of the Upper Main Lode. Continued exploration success offers a high-probability pathway to convert these newly defined intact zones directly into the active Endeavor mining inventory.

Shares looking cheap

Shaw and Partners has a $1.15 price target on Polymetals shares, which they reduced from $1.62 due to a fall in commodity prices.

The shares are currently changing hands for 75.5 cents. The company is valued at $230.6 million.

The post Buy this ASX mining stock for a 50%+ return: Broker appeared first on The Motley Fool Australia.

More reading

• Qube Holdings: Supreme Court approves takeover scheme
• Summerset Group delivers Q2 update
• West African Resources posts June 2026 quarter gold production update
• Lynas Rare Earths inks $50m deal for new Malaysian magnet factory
• Netwealth posts strong FUA growth and secures Morgan Stanley platform deal

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Turaco Gold Ltd (ASX: TCG) has caught the eye of a few brokers recently, after it released a positive prefeasibility study for its Afema Gold Project in southeast Côte d'Ivoire.

This time, we're having a look at what the team at Morgans is saying about the company and how much they think its shares are worth.

First, let's look at the company's project.

New mine to drive share price growth

Turaco earlier this month declared a maiden ore reserve of 1.91 million ounces of gold, which it says will sustain a mine producing more than 200,000 ounces of gold per year.

And in terms of the mine's revenue generation, the company published figures for a range of gold prices, but at US$4,000 per ounce – close to the current spot price of US$4,071.84 – the mine would generate gross revenue of US$8.095 billion over its life of 10.3 years.

The project would also have a payback period of 10 months, or 17 months if the gold price was US$3,000 per ounce.

Turaco said there was the possibility of extensions to the mineral resources, with all deposits open at depth and along strike, and there were also "numerous" additional exploration targets.

The company has immediately started a definitive feasibility study, which will also include commencing detailed design and engineering.

On the exploration front, the company will be continuing drilling with between three and five rigs operating.

Turaco Managing Director Justin Tremain said regarding the study:

In just a little over 2 years since acquiring Afema, the Turaco team has not only delivered extraordinary JORC Resource growth to 4.65 million ounces but has now also delivered a detailed development study with a maiden JORC Probable Ore Reserve estimate of just under 2 million ounces of gold based on a conservative gold price of US$2,000/oz and an AISC of just over US$1,500/oz, all within a granted mining permit. This progress is unmatched. The Study is the culmination of an extensive body of work including over 100,000m of drilling, comprehensive metallurgical variability test work, geotechnical test work, process and mine design, costing and scheduling.

Mr Tremain said the company was aiming to finish the definitive feasibility study by the second quarter of calendar year 2027 and to commence early works to allow first gold production in 2029.

Shares still looking cheap

The team at Morgans likes the project, but has sharply downgraded its price target for the company in its recent note to clients.

The analysts said:

While the prefeasibility study reinforces our conviction in Afema, following the transition of coverage, we have updated our forecasts to reflect the study outcomes and revised our valuation methodology. We also revise our recommendation to speculative buy, reflecting our reassessment of sovereign risk, together with the increased funding and execution risks associated with TCG's transition from explorer to developer.

Morgans has a price target of $1.18 on Turaco shares, compared to $2.19 previously.

Macquarie also recently published a research report on Turaco with a price target of $1 per share.

Turaco shares are currently valued at 47 cents. The company is valued at $506.2 million.

The post Want a 151% return? One broker thinks this ASX gold company could deliver appeared first on The Motley Fool Australia.

More reading

• 7 ASX shares downgraded by brokers this week
• 4 Africa-focused ASX gold stocks Macquarie says could outperform
• 8 ASX shares with 30% to 220% upside ahead: Experts
• Macquarie says this ASX gold stock can return better than 80%

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia has recommended Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Shares in Clarity Pharmaceuticals Ltd (ASX: CU6) were trading more than 10% higher in early trade on Monday after the company said it was going to present data from studies of its prostate cancer detection compound at an esteemed European medical conference.

But what was perhaps more compelling in the company's announcement was a first-person account from a patient who had used the company's compound and had benefited greatly from it.

New detection methods being developed

Clarity has developed two radiopharmaceutical compounds called 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA, whose studies to date show they perform well compared with existing detection methods.

The company said it will present various data relating to the compounds at the European Association of Nuclear Medicine (EANM) Annual Congress 2026, which is being held in October in Vienna.

The biotechnology company said regarding the conference:

EANM 2026 Annual Congress is one of the world's leading nuclear medicine conferences and the acceptance of these abstracts is testament to the strength of the data generated by Clarity's products and the promising prospects for SAR-bisPSMA to change the paradigm in the diagnosis and treatment of prostate cancer.

The company said one of its trials, which will be presented, "demonstrated improved diagnostic performance of 64Cu-SAR-bisPSMA next-day imaging vs. 68Ga-PSMA-11 across all key parameters assessed, including mean number of lesions per participant, total number of lesions, true positive rate and proportion of participants with a positive scan''.

The company will also present data from three client case studies, and said the use of its compound "changed planned clinical management in all three patients''.

One of the patients, Steve Hunter, also supplied a testimonial.

Compelling first-person account

Mr Hunter said he was diagnosed with prostate cancer in 2016, and while his initial treatment was quite successful, blood tests revealed in 2023 that his cancer had returned.

He said:

With SOC PSMA imaging currently available, no lesions were detectable. I was informed by more than one doctor that what I had was a micro-metastatic version of prostate cancer; that is, I had a large number of cancers too small to be detected.

Mr Hunter, himself a medical professional with a history including oncology research, approached Clarity with a view to trying its technology.

He said:

The results were beyond my expectations. Three tumours were found and I underwent targeted external beam radiation. Since then, I have repeated this process with Clarity and (Dr Alan Taylor's) support a few times to scan, find and subsequently treat the ensuant small number of tumours that arise, with stereotactic radiation therapy. I am so grateful to Clarity in making these scans available. This approach has proven to be highly successful by allowing me to obtain clear information about my disease and defer requiring ADT therapy and all the associated side effects with this treatment.

Clarity shares were trading 14.1% higher at $2.07.  

The post Why is this ASX biotech charging more than 10% higher? appeared first on The Motley Fool Australia.

More reading

• Qube Holdings: Supreme Court approves takeover scheme
• Summerset Group delivers Q2 update
• West African Resources posts June 2026 quarter gold production update
• Lynas Rare Earths inks $50m deal for new Malaysian magnet factory
• Netwealth posts strong FUA growth and secures Morgan Stanley platform deal

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Forrestania Resources Ltd (ASX: FRS) has agreed to buy the Edna May Gold Hub from Ramelius Resources Ltd (ASX: RMS) in a deal worth $300 million in cash and scrip.

Transformational gold opportunity

Under the deal, Forrestania will pay Ramelius $200 million in cash and $100 million in its own shares for the hub, which includes the 2.9 million tonne per annum Edna May mill, associated infrastructure, and the existing 945,000 ounce gold resource.

The company said the deal complements its Lake Johnston processing hub, which is currently undergoing refurbishment.

Forrestania Chair David Geraghty said regarding the deal:

This transaction upholds Forrestania's strategy to consolidate the proven and prospective gold assets in the Forrestania region. Approximately 12 months ago, Forrestania embarked on an aggressive M&A strategy to consolidate stranded high-quality gold assets and underexplored tenure surrounding Edna May. This strategy has been incredibly successful and set Forrestania up for today's acquisition. Forrestania believes it has the proven development and delivery team that is ready to refurbish, upgrade and commission the 2.9Mtpa Edna May Mill going forward. This work will be completed in conjunction with Forrestania's commissioning of Lake Johnston which is on-track for late 2026.

Forrestania said it was targeting a restart of the Edna May mill in the first half of 2027.

Forrestania shares were in a trading halt on Monday while the company completed a $300 million capital raise to fund the deal.

The company said it was targeting more than 6 million tonnes of ore processing capacity by the first half of 2027, with the Lake Johnston facility on track for commissioning in the fourth quarter of 2026.

Building a bigger WA footprint

The company added:

With Forrestania already holding significant tenure and JORC Resources surrounding Edna May, the acquisition builds-out its dual processing hub-and-spoke network, increasing Forrestania's operational flexibility and ensuring the right ore goes to the right mill. With a permitted and existing processing plant and associated infrastructure, Edna May presents a compelling near-term restart opportunity and allows Forrestania to avoid the approvals burden, development timeline and increased capital intensity associated with greenfield developments.

Forrestania shares, which last changed hands for 42.5 cents, are expected to remain in a trading halt until Wednesday, July 1.

The company is currently valued at $569.2 million.

Ramelius shares were up 3% on the news.

Ramelius said in a statement to the ASX, "the transaction provides Ramelius with an opportunity to crystallise value from a non-core asset and further focus resources on its core business'', while also retaining exposure to Edna May through its equity in Forrestania.

The post This ASX gold company's aggressive M&A program continues with $300 million deal appeared first on The Motley Fool Australia.

More reading

• This ASX gold stock could soar 60% thanks to a big announcement
• 6 ASX gold stocks Morgans rates as a buy
• This beaten-down ASX gold stock is jumping on a $300 million deal
• 5 ASX 200 gold stocks to buy and hold amid the crashing gold price
• This ASX gold stock is rewarding shareholders with cash and shares, and it's not too late to buy in

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Investing for solid dividend yields can be a great strategy for some investors, and if you're looking to follow this strategy, selecting companies with solid underlying businesses and a track record of performance is a good place to start.

Companies in infrastructure or with infrastructure-like qualities can be good investments, as they tend to have businesses with a high barrier to entry and arguably good visibility of future revenues.

I've selected three companies that are currently paying dividend yields of better than 5% for you to consider.

AGL Energy Ltd (ASX: AGL)

AGL is one of the country's major energy suppliers, with a market position that ensures it is likely to have a steady stream of income over the long term, barring unforeseen events.

That's not to say the business does not have its challenges, with investing in the energy transition and managing energy supply and pricing all factoring into the company's financial performance.

The stock is down 13.9% over the past year to $8.42.

Managing Director Damien Nicks told a recent conference that the company was expecting growing demand from the data centre sector in the coming years, as the emerging industry's power needs doubled from current levels.

Mr Nicks said during the update that AGL expected underlying net profit to be $610 to $680 million, tightening the guidance from $580 to $680 million.

AGL currently pays a 5.81% trailing dividend yield, with its next dividend payment scheduled for September.

APA Group (ASX: APA)

Another energy company here, but this time in the gas pipeline game.

APA has performed quite well from a share price standpoint over the past year, adding 32.3% to be changing hands for $10.77.

That level is just higher than Macquarie's price target for the company, which it recently pegged at $10.41.

Encouragingly, Macquarie expects the APA dividend yield to grow from 5.7% this year to 5.9% by FY28.

One of the drivers for the company, Macquarie said, is the growth in data centre demand for power, and from the retirement of the nation's coal fleet.

Macquarie said the federal gas reservation policy also creates incentives for energy companies to develop new gas fields, while adding that APA has improving balance sheet capacity.

Stockland Corporation Ltd (ASX: SGP)

Morgan Stanley analysts see upside in Stockland's share price, with a price target of $4.90 compared with the current price of $4.32.

The broker thinks there could be some residential settlements headwinds for the property development company following recent interest rate increases and changes to tax laws in the Federal Budget.

They say Stockland has in the past mitigated downturns with land sell-downs or joint ventures, but say this might be far off at this stage.

They said:

We see limited scope for material land profits in FY27, as Kogarah/Waterloo/DCs all still require detailed planning, power, and/or tenant commitments. However, the FY28+ pipeline looks robust and could drive a higher weighting to development profits vs traditional resi over the next cycle.

Morgan Stanley is forecasting the Stockland dividend to stay steady at 25.2 cents out to FY28, which at the current share price is a 5.8% dividend yield.

The post Buy these 3 blue-chip shares for better than 5% dividend yields appeared first on The Motley Fool Australia.

More reading

• Property or ASX shares? Here's why I'd choose the share market
• How much is needed in superannuation to target a $70,000 annual passive income?
• Property prices are falling. Here are the ASX shares most affected
• How much do I need in superannuation to receive $5,500 per month in passive income?
• Top ASX 200 share of each market sector in FY26

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia has positions in and has recommended Apa Group. The Motley Fool Australia has recommended Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.